High-Dose Nusinersen for Spinal Muscular Atrophy
(2026)Objective
To evaluate superior efficacy of high-dose vs standard-dose nusinersen in infantile-onset SMA
Study Summary
• High-dose nusinersen (50mg loading/28mg maintenance) produced dramatically superior motor gains vs sham in infantile-onset SMA, with a 26-point CHOP-INTEND advantage at day 302.
Intervention
High-dose nusinersen (50mg IT loading, 28mg IT maintenance) vs sham procedure
Inclusion Criteria
Genetically confirmed 5q SMA, symptomatic infants <6 months or presymptomatic <6 weeks
Study Design
Arms: Array
Patients per Arm: ~50 high-dose, ~25 sham (Part B total 75)
Outcome
Primary: CHOP-INTEND change +15.1 vs -11.1 (difference 26.19, 95% CI 20.7–31.74, P<0.0001). More milestones achieved in treated infants. Improved ventilation-free survival.
Bottom Line
High-dose nusinersen (50mg loading/28mg maintenance) produced dramatically superior motor gains vs sham in infantile-onset SMA, with a 26-point CHOP-INTEND advantage at day 302.
Major Points
- Phase 2/3 adaptive design testing high-dose nusinersen in infantile-onset SMA. Part B (confirmatory): 75 infants randomized to high-dose vs sham.
- Primary endpoint: CHOP-INTEND change +15.1 (high-dose) vs -11.1 (sham), treatment difference 26.19 points (95% CI 20.7–31.74, P<0.0001).
- Sham group declined by 11 CHOP-INTEND points, highlighting devastating natural history of untreated SMA Type 1.
- Motor milestones (sitting, standing) achieved by more treated infants, particularly in presymptomatic cohort.
- Ventilation-free survival improved with treatment.
- Supports dose optimization of intrathecal ASO therapy — higher doses produce greater SMN protein and better outcomes.
Study Design
- Study Type
- Randomized, double-blind, sham-controlled
- Randomization
- Yes
- Blinding
- Double-blind
- Sample Size
- 75
- Follow-up
- Day 302 (primary), extended follow-up ongoing
Primary Outcome
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| -11.1 | +15.1 | - | <0.0001 |
Limitations & Criticisms
- Sham-controlled design raises ethical questions in a disease with approved therapy, though justified by dose-finding rationale
- Exact numbers per arm not clearly reported in abstracts — full publication needed for precise data
- Presymptomatic and symptomatic cohorts analyzed separately — limits overall sample size per analysis
- Long-term durability and comparison with gene therapy (onasemnogene) not addressed
- Higher dose means more frequent lumbar punctures — practical burden on families
Citation
Nat Med. 2026.